Six or more FDA decisions on oncology drugs are due in 2026, covering antibody-drug conjugates, checkpoint inhibitors, and precision small molecules — the densest approval calendar since the immuno-oncology wave of the mid-2010s.
ADC frontrunners include Ifinatamab Deruxtecan and Ziihera, both approaching PDUFA deadlines. CR-001 ADC combinations extend the pipeline into 2027. Checkpoint inhibitor Tecentriq and PI3K inhibitor Gedatolisib complete the near-term slate.
At EHA 2026, AbbVie reported venetoclax plus obinutuzumab achieved a median eight years to next treatment in previously untreated chronic lymphocytic leukemia.1 That durability signal is among the strongest recorded in hematologic malignancy and reinforces the global case for combination regimens.
Bispecific antibody epcoritamab is advancing in follicular lymphoma. Selinexor, an exportin-1 inhibitor, is under evaluation in the SENTRY trial — adding mechanistic diversity to the binary event calendar.
The longest-horizon catalyst bridges oncology and metabolic disease. Century Therapeutics' CNTY-813 targets type 1 diabetes, which affects nine million people worldwide.2 Current islet transplantation achieves insulin independence in roughly 70% of patients at one year but requires lifelong immunosuppression.2 Preclinical data presented at ADA 2026 showed CNTY-813 delivered durable glucose control and immune evasion under alloimmune pressure — a differentiated profile versus existing cell therapies.
The ASCEND proof-of-concept readout is expected Q1 2027, offering staged exposure to next-generation modalities beyond the current PDUFA cluster.
FDA approvals carry global weight. Positive PDUFA outcomes typically trigger regulatory filings to the EMA, Japan's PMDA, and China's NMPA within 12–24 months. For patients in markets where access depends on US precedent, 2026 decisions directly shape availability timelines across Europe, Asia, and beyond.
For investors globally, the setup is structurally familiar: concentrated binary events, asymmetric payoffs, and cross-modality diversification. ADCs, bispecifics, iPSC cell therapies, and exportin inhibitors carry distinct mechanisms — and distinct failure modes. No single approval validates the others.
Positioning ahead of PDUFA dates — not chasing post-approval moves — is where the asymmetry sits.3
